



PRESS RELEASE

Moberg Pharma appoints new VP Pharmaceutical Innovation & Development

STOCKHOLM, June 23th, 2021, Moberg Pharma AB (OMX: MOB) announces the appointment of Agneta Larhed as Vice President Pharmaceutical Innovation & Development of Moberg Pharma. Dr Larhed will be joining the management team at Moberg Pharma in September.

Dr Larhed has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including the Swedish MPA, Orexo and Q-Med. Dr Larhed is a pharmacist and obtained her PhD in Pharmaceutics from Uppsala university. She is also an expert in the European Pharmacopoeia expert group nr 12 Dosage forms and pharmaceutical technical procedures. She replaces Torbjörn Wärnheim, who leaves the company after eight years at Moberg Pharma.

"I am very pleased that Agneta has chosen to work with us at Moberg Pharma. We are working intensively towards the goal to submit a registration application during the second half of 2021 in Europe for MOB-015. Agneta's solid experience from development and registration of novel treatments will be very valuable. I would like to thank Torbjörn for his many contributions to Moberg Pharma and wish him success with new challenges", says Anna Ljung, CEO Moberg Pharma.

For additional information, please contact:

Anna Ljung, CEO, telephone: +46 707 66 60 30, e-mail: anna.ljung@mobergpharma.se

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 a.m. CET on June 23th, 2021.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).